Intervention Review

You have free access to this content

Coenzyme Q10 for heart failure

  1. Mohammed E Madmani1,*,
  2. Ahmad Yusuf Solaiman2,
  3. Khalil Tamr Agha3,
  4. Yasser Madmani4,
  5. Yasser Shahrour5,
  6. Adib Essali6,
  7. Waleed Kadro7

Editorial Group: Cochrane Heart Group

Published Online: 2 JUN 2014

DOI: 10.1002/14651858.CD008684.pub2


How to Cite

Madmani ME, Yusuf Solaiman A, Tamr Agha K, Madmani Y, Shahrour Y, Essali A, Kadro W. Coenzyme Q10 for heart failure. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD008684. DOI: 10.1002/14651858.CD008684.pub2.

Author Information

  1. 1

    Case Western Reserve University/MetroHealth Medical Center Campus, Department of internal medicine, Cleveland, OH, USA

  2. 2

    Wayne State University, Neurology Department, Detroit, MI, USA

  3. 3

    Damascus University-Medical College, Faculty of Medicine, Damascus, Syrian Arab Republic

  4. 4

    Heart Group, London, UK

  5. 5

    Damascus, Syrian Arab Republic

  6. 6

    Modern Psychiatry Hospital, Psychiatry Centre, Damascus, Syrian Arab Republic

  7. 7

    The Golden Cardiovascular Centre, Damascus, Syrian Arab Republic

*Mohammed E Madmani, Department of internal medicine, Case Western Reserve University/MetroHealth Medical Center Campus, Cleveland, OH, USA. eid.madmani@ymail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 2 JUN 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Adarsh 2008 {published data only}
Berman 2004 {published data only}
Keogh 2003 {published data only}
  • Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao YC, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation 2003;12(3):135-41.
Khatta 2000 {published data only}
  • Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R, Robinson SW, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine 2000;132(8):636-40.
Kocharian 2009 {published data only}
  • Kocharian A, Shabanian R, Rafiei-Khorgami M, Kiani A, Heidari-Bateni G, Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young 2009;19(5):501-6.
Morisco 1993 {published data only}
  • Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator 1993;71(8 Suppl):S134-6.
Munkholm 1999 {published data only}

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Azuma 1992 {published data only}
Baggio 1993 {published data only}
  • Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure (interim analysis). The CoQ10 Drug Surveillance Investigators. Clinical Investigator 1993;71(8 Suppl):S145-9.
Belardinelli 2005 {published data only}
Belardinelli 2008 {published data only}
Cascone 1985 {published data only}
  • Cascone A, Cascone G, Alaimo A. Treatment of patients with congestive heart failure with coenzyme Q10 in an open trial [Italian]. Bollettino Chimico Farmaceutico 1985;124(5):43S-52S.
Chew 2008 {published data only}
  • Chew GT, Watts GF, Davis TME, Stuckey BGA, Beilin LJ, Thompson PL, et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008;31(8):1502-9.
Davini 1992 {published data only}
  • Davini A, Cellerini F, Topi PL. Coenzyme Q10: contractile dysfunction of the myocardial cell and metabolic therapy [Italian]. Minerva Cardioangiologica 1992;40(11):449-53.
Hall 1990 {published data only}
  • Hall JH, Judy WV, Folkers K. Long-term survival in coenzyme-Q10 treated congestive-heart-failure patients. Circulation 1990;82(4):675.
Hanping 1997 {published data only}
  • Hanping Z, Guolong Y, Jing L, Jin H. The changes of PRA, ATII, ALD, ET and ANP in patients with left ventricular and intervention with enalapril. Bulletin of Hunan Medical University 1997;22(4):323-6.
Hofman-Bang 1995 {published data only}
  • Hofman-Bang C, Rehnqvist N, Swedberg K, Wiklund I, Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. Journal of Cardiac Failure 1995;1:101-7.
Ishiyama 1976 {published data only}
Iwabuchi 1972 {published data only}
  • Iwabuchi T. Clinical efficacy of coenzyme Q10 for cardiac failure: a double-blind controlled comparison. Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine) 1972;49(9):2604-8.
Khatta 1999 {published data only}
  • Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger RS, Robinson SW, et al. Long-term efficacy of coenzyme Q 10 therapy for congestive heart failure. Circulation 1999;100(18):3411.
Kumar 2007 {published data only}
  • Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, et al. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiologica 2007;62(4):349-54.
Lampertico 1993 {published data only}
  • Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme-Q(10) as adjuvant therapy in heart-failure. Clinical Investigator 1993;71(8):S129-33.
Langsjoen 1985 {published data only}
  • Langsjoen PH, Vadhanavikit S, Folkers K. Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drugs Under Experimental & Clinical Research 1985;11(8):577-9.
Langsjoen 1985a {published data only}
  • Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proceedings of the National Academy of Sciences of the United States of America 1985;82(12):4240-4.
Langsjoen 1988 {published data only}
Langsjoen 1990 {published data only}
Langsjoen 1994 {published data only}
  • Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Molecular Aspects of Medicine 1994;15 Suppl:s165-75.
Langsjoen 2008 {published data only}
Manzoli 1990 {published data only}
  • Manzoli U, Rossi E, Littarru GP, Frustaci A, Lippa S, Oradei A, et al. Coenzyme Q10 in dilated cardiomyopathy. International Journal of Tissue Reactions 1990;12(3):173-8.
Mazzola 1987 {published data only}
  • Mazzola C, Guffanti EE, Vaccarella A. Noninvasive assessment of coenzyme Q 10 in patients with chronic stable effort angina and moderate heart failure. Current Therapeutic Research, Clinical and Experimental 1987;41(6):923-32.
Morisco 1994 {published data only}
  • Morisco C, Nappi A, Argenziano L, Sarno D, Fonatana D, Imbriaco M, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Molecular Aspects of Medicine 1994;15 Suppl:s155-63.
Mortensen 1985 {published data only}
  • Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Under Experimental & Clinical Research 1985;11(8):581-93.
Nishimura 1996 {published data only}
  • Nishimura T, Hori M. Therapeutic effects of coenzyme Q10 on dilated cardiomyopathy: assessment by 123I-BMIPP myocardial single photon emission computed tomography (SPECT): a multicenter trial in Osaka University Medical School Group [Japanese]. Kaku Igaku (Japanese Journal of Nuclear Medicine) 1996;33(1):27-32.
Permanetter 1992 {published data only}
  • Permanetter B, Rossy W, Klein G, Weingartner F, Seidl KF, Blomer H. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. European Heart Journal 1992;13(11):1528-33.
Poggesi 1991 {published data only}
  • Poggesi L, Galanti G, Comeglio M, Toncelli L, Vinci M. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. A medium-term randomized double-blind study versus placebo. Current Therapeutic Research, Clinical and Experimental 1991;49(5):878-86.
Sacher 1997 {published data only}
  • Sacher HL, Sacher ML, Landau SW, Kersten R, Dooley F, Sacher A, et al. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. American Journal of Therapeutics 1997;4(2-3):66-72.
Schneeberger 1984 {published data only}
  • Schneeberger W, Zilliken F, Moritz J. Clinical studies with coenzyme Q10 in patients with congestive heart failure. Drugs Under Experimental and Clinical Research 1984;10(7):503-12.
Sinatra 2000 {published data only}
Sinatra 2004 {published data only}
Watson 1999 {published data only}
  • Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. Journal of the American College of Cardiology 1999;33(6):1549-52.
Witte 2005 {published data only}
  • Witte KK, Nikitin NP, Parker AC, Von Haehling S, Volk HD, Anker SD, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. European Heart Journal 2005;26(21):2238-44.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Arnold 2006
  • Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Canadian Journal of Cardiology 2006;22(1):23-45.
Belch 1991
Berthold 2006
  • Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Safety 2006;29(8):703-12.
Bhagavan 2007
Boon 2006
  • Boon NA, Colledge NR, Walker BR, Hunter JAA. Davidson's Principles and Practice of Medicine. 20th Edition. Churchill Livingstone, 2006.
Carbajal 2003
  • Carbajal EV, Deedwania PC. Congestive heart failure. In: Crawford MH editor(s). Current Diagnosis and Treatment in Cardiology. 2nd Edition. New York: Lange Medical Books/McGraw-Hill, 2003:218-9.
Clinical Evidence
  • BMJ Clinical Evidence. EBM Tools: Glossary. http://clinicalevidence.bmj.com/ceweb/resources/glossary.jsp#Random_effects (accessed 16 January 2010).
Diaz-Velez 1996
  • Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. American Heart Journal 1996;131(1):146-52.
Drexler 2004
  • Drexler H, Hasenfuss G. Physiology of the normal and failing heart. In: Crawford MH, DiMarco JP, Paulus WJ editor(s). Cardiology. 2nd Edition. Edinburgh: Mosby, 2004:829.
Egger 1997
Elesber 2001
Folkers 1990
  • Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, et al. Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of Sciences of the United States of America 1990;87(22):8931-4.
Gottdiener 2002
Greenberg 1990
Heck 2000
  • Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. American Journal of Health-System Pharmacy 2000;57(13):1221-7.
HFSA 2006
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Ho 1993
Hunt 2005
  • Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
Kishi 1977
  • Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. Research Communications in Chemical Pathology and Pharmacology 1977;17(1):157-64.
Lefebvre 2011
  • Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Lloyd-Jones 2010
  • WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010;121:e46-215.
Massie 1997
  • Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. American Heart Journal 1997;133:703-12.
McMurray 1990
  • McMurray J, McLay J, Chopra M, Bridges A, Belch JJ. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology 1990;65(18):1261-2.
McMurray 1993
McMurray 1998
  • McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. European Heart Journal 1998;19 Suppl P:P9.
Migliore 2004
  • Migliore L, Molinu S, Naccarati A, Mancuso M, Rocchi A, Siciliano G. Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. Mutagenesis 2004;19(1):43-9.
Moher 1998
Mortensen 1984
  • Mortensen SA, Vadhanavikit S, Folkers K. Deficiency of coenzyme Q10 in myocardial failure. Drugs Under Experimental and Clinical Research 1984;X(7):497-502.
Mortensen 1990
  • Mortensen SA, Vadhanavikit S, Muratsu K, Folkers K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. International Journal of Tissue Reactions 1990;12(3):155-62.
Mortensen 1993
Mortensen 1997
  • Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Molecular Aspects of Medicine 1997;18(Suppl):S137-44.
Niklowitz 2007
  • Niklowitz P, Sonnenschein A, Janetzky B, Andler W, Menke T. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage. International Journal of Biological Sciences 2007;3(4):257-62.
Nishiyama 1998
NYHA 1964
  • Criteria Committee, New York Heart Association. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th Edition. Boston: Little, Brown and Co, 1964.
Rauchova 1995
  • Rauchova H, Drahota Z, Lenaz G. Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiological Research 1995;44(4):209-16.
Redfield 2003
  • Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289(2):194-202.
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Richardson 1996
  • Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 Word Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-2.
Rodriguez 2004
  • Rodriguez-Artalejo F, Banegas Banegas JR, Guallar-Castillon P. Epidemiology of heart failure [Epidemiologia de la insuficiencia cardiaca]. Revista Espanola de Cardiologia 2004;57(2):163-70.
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Singh 1999
  • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(2):203-8.
Swedberg 2005
  • Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. European Heart Journal 2005;26(11):1115-40.
Tappel 1972
Teerlink 1991
Tsutsui 2002
  • Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. Journal of the American College of Cardiology 2002;39(6):957-62.
Vasan 1995
  • Vasan RS, Benjamin EJ, Levy D. Prevalence clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. Journal of the American College of Cardiology 1995;26(7):1565-74.
Ware 2005